Related Experiment Videos
Peripheral nitric oxide in carrageenan-induced inflammation
K Omote1, K Hazama, T Kawamata
1Department of Anesthesiology, Sapporo Medical University School of Medicine, South-1, West-16, Chuoku, 060-8543, Sapporo, Japan. komote@sapmed.ac.jp
Brain Research
|September 5, 2001
Summary
Carrageenan-induced inflammation involves peripheral nitric oxide (NO) release. Neuronal NOS (nNOS) dominates early NO production, while both nNOS and inducible NOS (iNOS) contribute later in inflammation.
Area of Science:
- Pharmacology
- Neuroscience
- Inflammation Research
Background:
- Peripheral nitric oxide (NO) production by nitric oxide synthase (NOS) isoforms is implicated in inflammatory processes like edema and hyperalgesia.
- Understanding the specific roles of NOS isoforms in NO release during inflammation is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the temporal effects of different nitric oxide synthase (NOS) isoforms on nitric oxide (NO) release during carrageenan-induced inflammation in rats.
- To elucidate the contribution of neuronal NOS (nNOS) and inducible NOS (iNOS) to NO production in acute inflammation.
Main Methods:
- Utilized a microdialysis technique in Sprague-Dawley rats to measure nitrite and nitrate (NO2-/NO3-) levels in hindpaw skin.
- Administered carrageenan to induce inflammation and employed NOS inhibitors (L-NMMA, AG) and sciatic nerve sectioning to differentiate isoform contributions.
Main Results:
- Carrageenan significantly elevated NO2-/NO3- concentrations for over 8 hours.
- Non-selective NOS inhibition (L-NMMA) blocked the increase, while iNOS inhibition (AG) showed delayed suppression.
- Sciatic nerve denervation significantly reduced NO2-/NO3- levels, particularly in the early stages of inflammation.
Conclusions:
- Carrageenan triggers peripheral NO release mediated initially by nNOS and subsequently by both nNOS and iNOS.
- These findings highlight the dynamic role of NOS isoforms in the inflammatory response and suggest potential therapeutic targets.